Compare SLRC & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLRC | FDMT |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 803.0M | 695.3M |
| IPO Year | 2007 | 2019 |
| Metric | SLRC | FDMT |
|---|---|---|
| Price | $13.24 | $11.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $15.14 | ★ $31.71 |
| AVG Volume (30 Days) | 455.3K | ★ 1.0M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 10.49% | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ 0.31 | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | $1.09 | N/A |
| Revenue Next Year | N/A | $70.28 |
| P/E Ratio | $42.26 | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $12.13 | $4.15 |
| 52 Week High | $16.75 | $14.00 |
| Indicator | SLRC | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 59.08 | 52.07 |
| Support Level | $12.83 | $8.39 |
| Resistance Level | $13.41 | $11.85 |
| Average True Range (ATR) | 0.26 | 0.93 |
| MACD | 0.12 | -0.17 |
| Stochastic Oscillator | 92.13 | 23.17 |
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. The company's investment objective is to generate both current income and capital appreciation through debt and equity investments. The company invests principally in leveraged middle-market companies in the form of senior secured loans, financing leases, and to a lesser extent, unsecured loans and equity securities.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).